Amgen's Novel Weight Loss Drug Shows Potential for Longer Lasting Effect With Less Frequent Dosing Than Wegovy, Zepbound

In a Phase I trial, data suggest that Amgen’s maridebart cafraglutide (MariTide) may allow patients to take lower and less frequent doses over time while still maintaining significant weight loss.

Source link
#Amgen039s #Weight #Loss #Drug #Shows #Potential #Longer #Lasting #Effect #Frequent #Dosing #Wegovy #Zepbound